المؤلفون: Sandra L. Vale, BSc, Maria Said, RN, Jill Smith, BSc, Preeti Joshi, PhD, Richard KS. Loh, FRACP

المصدر: World Allergy Organization Journal, Vol 15, Iss 11, Pp 100706- (2022)

مصطلحات موضوعية: National Allergy Strategy, Funding, Kotter's Change Model, Allergy, Strategy, Advocacy, Immunologic diseases. Allergy, RC581-607

الوصف: Background: Allergic diseases have become an increasing health issue worldwide, being one of the fastest growing chronic diseases in Australia and other westernized countries. In 2013, allergic diseases were reported to affect 20% of the Australian population. Despite the high prevalence there was no national strategy to address these complex health issues, to enable the health system to manage the increasing number of patients. This project aimed to develop and implement a national strategy to improve allergy management in Australia, with a view of improving the quality of life of people living with or caring for someone with allergic diseases. Methods: The need for a national strategy to improve allergy management was identified. The Australasian Society of Clinical Immunology and Allergy (ASCIA) and Allergy & Anaphylaxis Australia (A&AA) worked together as partners to progress a national strategy using a theoretical model to underpin its development. Unrestricted education grants were sought to fund engagement with stakeholder organizations for both development and implementation summits. Several stages of advocacy were undertaken. Results: The National Allergy Strategy was developed as a partnership between ASCIA and A&AA. The Kotter's Change Management Model provided the basis for the steps undertaken to develop and implement the National Allergy Strategy. Two Allergy Summits, one for development and the other for implementation, were held. Several events were held to advocate for federal government funding. Five individual funding grants were achieved to implement National Allergy Strategy projects addressing the most urgent issues. Conclusion: The development of the National Allergy Strategy, a partnership between ASCIA and A&AA, was important in enabling successful advocacy for funding and implementation of important Australia-wide projects. The partnership has also helped facilitate engagement with key stakeholders to help advocate for funding and provide guidance and expertise in project implementation and resource development. The National Allergy Strategy has been successful in attracting funding to implement projects and develop resources urgently needed. The National Allergy Strategy has also provided a framework and a collaborative approach, for advocacy for further funding and future work to be undertaken.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S1939455122000825Test; https://doaj.org/toc/1939-4551Test

الوصول الحر: https://doaj.org/article/8b3f6b51b0424852bab9b3e43566fc7fTest

المؤلفون: Preeti Joshi, Katie Frith, Sandra Vale, Lara S. Ford, Jill Smith

المصدر: Australian Prescriber

مصطلحات موضوعية: Allergy, Clinical immunology, business.industry, Fatal anaphylaxis, medicine.disease, allergy, Article, adrenaline (epinephrine) injector device, Epinephrine, adrenaline (epinephrine), Anesthesia, medicine, anaphylaxis, Pharmacology (medical), Acute management, business, Anaphylaxis, medicine.drug

الوصف: SUMMARY Severe allergic reactions (anaphylaxis) are unpredictable, and initial signs of what could be fatal anaphylaxis can be mild Adrenaline (epinephrine) remains the first-line drug of choice for the acute management of anaphylaxis and should be administered early There are no contraindications to intramuscular adrenaline in the treatment of anaphylaxis Correct positioning of the patient is vital as death can occur within minutes if a patient stands, walks or sits up suddenly. Position the patient correctly first and then promptly administer intramuscular adrenaline Updated guidelines by the Australasian Society of Clinical Immunology and Allergy now recommend that the 0.15 mg adrenaline injector device may be prescribed for infants and children weighing 7.5–10 kg. The recommendation to use the 0.3 mg adrenaline injector device for those over 20 kg remains unchanged The adrenaline doses in Australian Prescriber’s anaphylaxis wallchart remain valid

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dc74584a68b8d04abe62be69e9cf99fTest
https://pubmed.ncbi.nlm.nih.gov/34211247Test